SW · GSK.SW
GlaxoSmithKline plc
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Brentford TW8 9GS
- Website
- gsk.com
Price · as of 2022-12-31
$19.98
Market cap 101.55B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2008 | $0.00 | $16.90 | |||
| 2009 | $0.00 | $35.60 | |||
| 2010 | $0.00 | $4.00 | |||
| 2011 | $0.00 | $6.80 | |||
| 2012 | $0.00 | $6.30 | |||
| 2013 | $0.00 | $13.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $27.70 | |||
| 2016 | $0.00 | $7.00 | |||
| 2017 | $0.00 | $9.50 | |||
| 2018 | $0.00 | $11.10 | |||
| 2019 | $0.00 | $24.30 | |||
| 2020 | $0.00 | $15.40 | |||
| 2021 | $0.00 | $11.10 | |||
| 2022 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates GlaxoSmithKline plc's (GSK.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $19.98
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About GlaxoSmithKline plc
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
- CEO
- Emma N. Walmsley
- Employees
- 0
- Beta
- 0.00
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $19.98) − 1 = — (DCF, example).